Cite
HARVARD Citation
Gray, M. et al. (2016). Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast cancer research. 18 (1), pp. 1-14. [Online].